Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS
(Bloomberg) -- Novartis AG has launched legal attacks on about two dozen generic-drug makers in a move to protect U.S. sales of its best-selling branded drug.
The lawsuits, filed in federal court in Wilmington, Delaware, come just days after Novartis won a patent case last week that had challenged the originality of a patent on Novartis's Gilenya drug, used for treating multiple sclerosis.
Novartis is seeking court orders blocking any potential generic versions of Gilenya until the patent has expired, in December 2027, and to collect damages if copies are made before then. Gilenya's main patent expires in August 2019. Defendants include Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd. and Mylan NV.
Gilenya, whose active ingredient is fingolimod, had U.S. sales of $1.7 billion in 2017, accounting for 3.5 percent of company revenue, according to data compiled by Bloomberg.
The lawsuits, which allege infringement, weren't unexpected after the U.S. Patent and Trademark Office's review board rejected claims by four generic companies related to the patent on the dosing of the drug, according to Michael Yee of Jefferies & Co. Novartis could lean on that victory to try to block generic competition, he said before the lawsuits were filed. It remains unclear if the generic companies will still launch rivals to Gilenya and risk costly damages.
“Since any potential generic product may infringe the dosage regimen patent which was upheld as valid by the US PTO, Novartis is asserting this patent,” said Eric Althoff, a spokesman for Novartis, based in Basel, Switzerland.
President Donald Trump praised Novartis on Thursday morning for holding off on price increases, a week after he attacked the company over its reported plans for a series of hikes.
“Thank you to Novartis for not increasing your prices on prescription drugs,” Trump wrote on Twitter. “Likewise to Pfizer.”
The cases are Novartis Pharmaceuticals Corporation v. Apotex Inc., 18-cv-1038; Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA Inc., 18-cv-1039; Novartis Pharmaceuticals Corporation v. Sun Pharmaceutical Industries Ltd., 18-cv-1040; and Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc., 18-cv-1043; U.S. District Court, Delaware (Wilmington).
--With assistance from Susan Decker and James Paton.
To contact the reporter on this story: Christopher Yasiejko in Wilmington, Delaware, at cyasiejko1@bloomberg.net
To contact the editors responsible for this story: David Glovin at dglovin@bloomberg.net, Larry Reibstein, Heather Smith
©2018 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.